Thymalfasin is under clinical development by SciClone Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Thymalfasin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Thymalfasin overview

Thymalfasin (Zadaxin) is a synthetic polypeptide consisting of 28 amino acids, a synthetic version of thymosin alpha 1, a substance found naturally in the circulation and produced in the body's thymus gland. It is formulated as an injection for the sub-cutaneous route of administration. It is used different indications such as chronic Hepatitis B, cancer adjuvant, vaccine enhancer and immunostimulant. It is used as an adjuvant for influenza vaccination in immunocompromised individuals.

Thymalfasin is under development for the treatment of solid tumor, acute pneumonia, thymoma, thymic carcinoma and sepsis. It was also under development for the treatment of advanced stage metastatic malignant melanoma (US) and non-small cell lung cancer.

SciClone Pharmaceuticals overview

SciClone Pharmaceuticals (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipeline products include thymalfasin for injection, zoledronic acid concentrated solution for injection, mesna injection, sunitinib malate capsules, dacomitinib tablets, medroxyprogesterone acetate tablets, miconazole muco-adhesive buccal tablets and irinotecan hydrochloride injection, among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. The company operates in Hong Kong, China, Singapore, the US, Italy and the Cayman Islands. SciClone is headquartered in Shanghai, China.

For a complete picture of Thymalfasin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.